Drug Utilization Study on the Prescribing Indications for Yasmin® and Other OCs in Croatia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01319500|
Recruitment Status : Completed
First Posted : March 21, 2011
Results First Posted : November 20, 2012
Last Update Posted : November 20, 2012
|Condition or disease|
Large, prospective non-interventional cohort studies with active surveillance of study participants indicate that many users of oral contraceptives use these preparations not only for contraception but also for the treatment of hormone-dependent diseases and symptoms - such as premenstrual dysphoric disorder, acne, endometriosis, ovarian cysts, polycystic ovary syndrome, bleeding disorders and painful periods. In the International Active Surveillance Study of Women Taking Oral Contraceptives (INAS) more than 30% of participants reported that they use their OC for contra¬ception as well as for the treatment of one of the mentioned conditions.
It is also conceivable that some women use OC not for contraception but only for one of these hormone-dependent conditions. In most instances the exclusive use for these conditions would constitute off-label use as only few preparations have a stand-alone approved indication for one of these conditions.
For many countries the actual extent of off-label use of OCs for these conditions is unknown. This applies also to Croatia. Therefore, the Croatian health authority requested a drug utilization study to investigate current prescribing indications for Yasmin® and other OCs in Croatia. The study details were agreed upon with the Croatian health authority.
|Study Type :||Observational|
|Actual Enrollment :||3776 participants|
|Official Title:||Drug Utilization Study on the Prescribing Indications for Yasmin® and Other OCs in Croatia|
|Study Start Date :||February 2009|
Users of the drospirenone/ethinylestradiol (DRSP/EE) containing OC "Yasmin"
Users of OCs except Yasmin ("Other OCs")
- OC Prescriptions by Treatment Group and Prescribing Medical Specialists [ Time Frame: February 2009 - March 2009 ]Prescriptions of Yasmin and Other OCs by different physicians (private gynecologists, public gynecologists and dermatologists)
- Reasons for OC Prescriptions [ Time Frame: February 2009 - March 2009 ]The main reasons for OC prescription: contraception only; contraception combined with non-contraceptive reasons; non-contraceptive reasons only.
- Non-contraceptive Reasons for OC Prescriptions (Reported by Women Who Used OCs for "Contraceptive and Non-contraceptive" and "Non-contraceptive Only" Reasons [ Time Frame: February 2009 - March 2009 ]Non-contraceptive reasons for OC prescriptions (including both categories: "contraception plus non-contraceptive reasons" and "non-contraceptive reasons only"
- Non-contraceptive Reasons for OC Prescriptions (Reported by Women Who Used OCs for Non-contraceptive Reasons Only) [ Time Frame: February 2009 - March 2009 ]Exclusively non-contraceptive reasons for OC prescriptions (no contraception intended; category "non-contraceptive reasons only"
- Reasons for OC Prescriptions by Gynecologists and Dermatologists [ Time Frame: February 2009 - March 2009 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01319500
|Center for Epidemiology and Health Research Berlin|
|Berlin, Germany, 10115|
|Principal Investigator:||Juergen C Dinger, MD, PhD||Berlin Center for Epidemiology and Health Research|